Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma

Mark A. Baxter (Lead / Corresponding author), Hilary Glen, Thomas R. J. Evans

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)
364 Downloads (Pure)


Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver accounting for approximately 90% of cases. Patients often present at an advanced stage when treatment options are limited. Sorafenib, a multitargeted tyrosine kinase inhibitor, has been the first-line treatment in this setting for almost a decade. Several subsequent targeted therapies have failed to demonstrate significant improvement in survival. The results of the REFLECT study suggest that lenvatinib, a multikinase inhibitor, may have promised as a first-line treatment in patients with advanced HCC. This article will review the development of lenvatinib and the evidence behind its potential use in patients with advanced HCC.
Original languageEnglish
Pages (from-to)2021-2029
Number of pages9
JournalFuture Oncology
Issue number20
Early online date22 May 2018
Publication statusPublished - Aug 2018


  • drug development
  • hepatocellular carcinoma
  • lenvatinib
  • multikinase inhibitor
  • pharmacokinetics
  • sorafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this